Literature DB >> 19589259

Ghrelin and obestatin levels in end-stage renal disease.

B Aygen1, A Dogukan, F E Dursun, S Aydin, N Kilic, F Sahpaz, H Celiker.   

Abstract

Malnutrition is fairly common in end-stage renal disease (ESRD) patients, persistent lack of appetite being a major symptom. Ghrelin and obestatin are two hormones that are involved in appetite and energy homeostasis. The present study examined ghrelin and obestatin levels in 24 ESRD patients undergoing haemodialysis and 24 age-matched healthy controls. Serum and saliva ghrelin and obestatin levels in the ESRD patients were significantly higher compared with controls, while saliva ghrelin and obestatin levels in all study participants were significantly higher than serum levels. Saliva ghrelin correlated with serum ghrelin and saliva obestatin correlated with serum obestatin in all study participants, although there was no correlation between ghrelin and obestatin levels. In conclusion, the results suggest that the kidneys may have a role in the metabolism and/or clearance of obestatin, as they do for ghrelin. Further studies are needed to determine if elevated levels of these hormones in ESRD patients contribute to the malnutrition that is common in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589259     DOI: 10.1177/147323000903700319

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  10 in total

1.  Comparison of serum and salivary ghrelin in healthy adults, morbidly obese, and patients with metastatic carcinoma.

Authors:  Frank Benedix; Sabine Westphal; Robert Patschke; Claus Luley; Hans Lippert; Stephanie Wolff
Journal:  Obes Surg       Date:  2011-08       Impact factor: 4.129

2.  Alterations in appetite-regulating hormones influence protein-energy wasting in pediatric patients with chronic kidney disease.

Authors:  Anja K Büscher; Rainer Büscher; Berthold P Hauffa; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2010-07-06       Impact factor: 3.714

3.  Ghrelin in chronic kidney disease.

Authors:  Wai W Cheung; Robert H Mak
Journal:  Int J Pept       Date:  2010-03-17

4.  Unacylated ghrelin and obestatin: promising biomarkers of protein energy wasting in children with chronic kidney disease.

Authors:  Alice Monzani; Michela Perrone; Flavia Prodam; Stefania Moia; Giulia Genoni; Sara Testa; Fabio Paglialonga; Anna Rapa; Gianni Bona; Giovanni Montini; Alberto Edefonti
Journal:  Pediatr Nephrol       Date:  2017-11-18       Impact factor: 3.714

5.  Phlorizin pretreatment reduces acute renal toxicity in a mouse model for diabetic nephropathy.

Authors:  Bas Brouwers; Vincent P E G Pruniau; Elisa J G Cauwelier; Frans Schuit; Evelyne Lerut; Nadine Ectors; Jeroen Declercq; John W M Creemers
Journal:  J Biol Chem       Date:  2013-08-11       Impact factor: 5.157

6.  Ghrelin for cachexia.

Authors:  Takashi Akamizu; Kenji Kangawa
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

7.  Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia.

Authors:  Timo D Müller; Diego Perez-Tilve; Jenny Tong; Paul T Pfluger; Matthias H Tschöp
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

Review 8.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

9.  Low serum concentration of obestatin as a predictor of mortality in maintenance hemodialysis patients.

Authors:  Ilia Beberashvili; Inna Sinuani; Ada Azar; Hadas Kadoshi; Gregory Shapiro; Leonid Feldman; Judith Sandbank; Zhan Averbukh
Journal:  Biomed Res Int       Date:  2013-09-12       Impact factor: 3.411

10.  Increased circulating obestatin in patients with chronic obstructive pulmonary disease.

Authors:  Yi Lei; Yasha Liang; Yifan Chen; Xiaojing Liu; Xiaoyang Liao; Fengming Luo
Journal:  Multidiscip Respir Med       Date:  2014-01-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.